Today: 10 April 2026
Subscribe
Browse Category

NYSE:JNJ 11 December 2025 - 23 December 2025

Johnson & Johnson (JNJ) Stock After Hours Today (Dec. 22, 2025): After-the-Bell Move, Key Headlines, and What to Watch Before Tuesday’s Open

Johnson & Johnson (JNJ) Stock After Hours Today (Dec. 22, 2025): After-the-Bell Move, Key Headlines, and What to Watch Before Tuesday’s Open

Johnson & Johnson closed Monday at $207.32, up 0.46%, with after-hours trading showing little movement on light volume. Investors tracked Washington’s drug-pricing push and new talc-litigation updates. Hedge funds turned more cautious on healthcare stocks, according to Reuters. NYSE will close early Wednesday and remain shut Thursday for Christmas.
23 December 2025
·
Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

Johnson & Johnson shares traded at $206.63 Monday after the European Commission approved TREMFYA for pediatric psoriasis, marking its first IL-23 inhibitor indication in children. The company also secured recent FDA approvals for RYBREVANT FASPRO in lung cancer and TRUFILL n-BCA for chronic subdural hematoma. Ongoing talc litigation continues to affect investor sentiment.
22 December 2025
·
Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson shares closed at $206.37 on Friday, about 4% below their 52-week high. A Minnesota jury awarded $65.5 million in a talc cancer case against the company, which plans to appeal. The FDA granted a priority review voucher for J&J’s Tecvayli-Darzalex multiple myeloma regimen, speeding regulatory timelines. Trading may see sharper moves this week due to holiday liquidity.
22 December 2025
Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson closed Friday, Dec. 19, 2025, at about $206 per share, as investors weighed U.S. drug-pricing negotiations and new talc verdicts against product pipeline momentum. The company is set to meet with the White House after the holidays over possible participation in the TrumpRx drug-pricing initiative. Trading volume is expected to be thin during the Christmas-shortened week.
21 December 2025
··
Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

A Minnesota jury awarded $65.5 million to a plaintiff who said Johnson & Johnson’s talc products caused mesothelioma, with J&J vowing to appeal. JNJ shares last traded at $206.37, down 0.9% from the prior close and about 3.6% below their December 15 record. Over 67,000 plaintiffs are suing J&J over similar claims. The company declared a $1.30 quarterly dividend for Q4 2025.
20 December 2025
·
Johnson & Johnson Stock After Hours Dec. 19, 2025: JNJ Ticks Up After the Bell—Key News, Forecasts, and What to Watch Before the Next Open

Johnson & Johnson Stock After Hours Dec. 19, 2025: JNJ Ticks Up After the Bell—Key News, Forecasts, and What to Watch Before the Next Open

Johnson & Johnson shares rose 0.51% to $207.43 in after-hours trading Friday, after closing down 0.9% in the regular session. The move followed late news on Washington drug-pricing talks, analyst targets, and litigation. JNJ was not among nine firms signing new Trump administration drug-pricing deals but was named as a company in ongoing discussions. U.S. markets are closed Saturday; trading resumes Monday.
20 December 2025
·
Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson shares hovered near $208 intraday on December 19, 2025, as investors weighed new U.S. drug-pricing talks involving the company, recent FDA approvals, and ongoing talc litigation. Reuters reported J&J remains in negotiations with the White House over prescription drug pricing reforms. The FDA approved Rybrevant Faspro for subcutaneous use in EGFR-mutated NSCLC.
19 December 2025
·
Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson shares closed Thursday at $208.31, down 0.96%, then edged up to $208.65 after hours. The company announced FDA clearance expanding TRUFILL n‑BCA’s use for chronic subdural hematoma and FDA approval for RYBREVANT FASPRO as a subcutaneous lung cancer treatment. JNJ’s market cap stands near $502 billion.
19 December 2025
·
Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

Johnson & Johnson shares traded near $210 on December 17, 2025, after a sharp drop the previous day and renewed analyst attention. RBC raised its price target to $240, maintaining an Outperform rating. The stock remains close to 2025 highs, with analysts split on near-term upside. JNJ continues to offer a quarterly dividend of $1.30 per share, yielding around 2%.
17 December 2025
·
Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson shares fell about 1% to $211–$212 late Tuesday morning after hitting recent highs, following news that the FDA granted a National Priority Voucher for its Tecvayli and Darzalex combination therapy for multiple myeloma. The FDA highlighted strong Phase 3 results and rapid review plans. Investors await the company’s upcoming earnings update for further guidance.
16 December 2025
···
Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson shares closed up 1.22% at $214.17 Monday and traded higher after hours following news that the FDA awarded a national priority voucher for its Tecvayli-daratumumab combination in relapsed/refractory multiple myeloma. The voucher, tied to strong Phase 3 MajesTEC-3 results, allows for accelerated FDA review. U.S. stocks overall ended slightly lower ahead of key economic data releases.
16 December 2025
·
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Eli Lilly reported late-stage trial success for its obesity drug retatrutide, with patients losing 28.7% of body weight over 68 weeks. Pfizer re-entered the obesity drug market through a $150 million licensing deal with Yao Pharma. The FDA moved to accelerate review of Lilly’s oral GLP-1 pill, orforglipron, possibly advancing a decision to March. The Fed cut rates by 25 basis points and signaled new Treasury purchases.
14 December 2025
······
Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson shares closed at $211.58 on Dec. 12, 2025, up 4.9% for the week after an FDA approval for AKEEGA in prostate cancer and new multiple myeloma data. The stock outperformed the broader market despite renewed talc litigation risk. A Federal Reserve rate cut earlier in the week supported large healthcare stocks. JNJ traded as high as $212.27 intraday Friday.
13 December 2025
··
Johnson & Johnson (JNJ) Stock News Today, Forecasts and Analyst Targets (Dec. 12, 2025)

Johnson & Johnson (JNJ) Stock News Today, Forecasts and Analyst Targets (Dec. 12, 2025)

Johnson & Johnson shares traded at $210.50 as of 14:33 UTC Friday, near Thursday’s all-time high close of $210.01. Wells Fargo and Morgan Stanley raised their price targets to $230 and $197, respectively, following similar moves by RBC, Citigroup, and HSBC. The average analyst target now sits just above the current price, with consensus ratings holding at “overweight.”
12 December 2025
·
Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson stock hit a 52-week high of about $208 on December 11, 2025, lifting its market cap above $500 billion after a rally that outpaced the S&P 500. The surge followed strong oncology trial results, new drug approvals, and optimism about offsetting Stelara sales declines. Legal risks and pricing pressures remain. JNJ’s dividend yield stands near 2.5%.
11 December 2025
·
Johnson & Johnson (JNJ) Stock After the Bell on December 10, 2025 – And What to Watch Before the December 11 Open

Johnson & Johnson (JNJ) Stock After the Bell on December 10, 2025 – And What to Watch Before the December 11 Open

Johnson & Johnson closed at $206.54 on Dec. 10, up 3.3% and less than 1% below its record high, after strong multiple myeloma drug data. After-hours trading edged the stock to $206.90, but premarket indications early Dec. 11 showed a drop to $202.50 on light volume. Year-to-date, JNJ has gained nearly 40%. The company faces ongoing talc litigation and regulatory scrutiny.
11 December 2025
··
1 … 4 5 6 7 8

Stock Market Today

  • White House Warns Staff Against Using Nonpublic Information for Prediction Market Bets
    April 9, 2026, 9:24 PM EDT. The White House Management Office emailed staff on March 24, warning against using nonpublic government information to place bets on online prediction markets like Kalshi or Polymarket. Such actions are a criminal offense and violate government ethics regulations designed to prevent insider trading and misuse of confidential data. The email stresses that improper financial gain by government employees will not be tolerated and directs staff to the White House Counsel for guidance. The move follows concerns over a spike in oil futures trading minutes before President Trump's March 23 announcement about postponing strikes on Iran's power plants, raising suspicions of potential insider trading. White House spokespeople dismissed allegations against officials, emphasizing a commitment to ethics and the public interest.

Latest article

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

9 April 2026
Meta Platforms signed a new $21 billion deal with CoreWeave for AI cloud computing capacity through 2032, according to a securities filing. CoreWeave shares rose 3.4% in after-hours trading. The agreement adds to a $14.2 billion commitment disclosed last September. CoreWeave also launched $3 billion in convertible notes and upsized a senior-notes deal to $1.75 billion.
Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

9 April 2026
Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.
NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

9 April 2026
NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.
Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

9 April 2026
Plug Power shares rose 2.5% to $2.715 Thursday after the company reaffirmed its target of positive EBITDAS by end-2026 and projected up to $200 million in savings from Project Quantum Leap. The update followed a major electrolyzer project win in Quebec and investor meetings in Toronto and Montreal. Plug reported 2025 revenue of $710 million and a fourth-quarter gross profit of $5.5 million.
Go toTop